Evidence mapPaperPMID 40142970Full record

ReviewPharmaceutics2025

Anti-Tumor Strategies of Photothermal Therapy Combined with Other Therapies Using Nanoplatforms.

Rubing Xu, Shengmei Wang, Qiuyan Guo, Ruqian Zhong, Xi Chen, Xinhua Xia

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Dynamic Hydrogels in Breast Tumor Models.Gels (Basel, Switzerland) · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rubing XuSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0009-0008-1194-5671
Shengmei WangThe First Hospital of Hunan University of Chinese Medicine, Changsha 410007, China.
Qiuyan GuoSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Ruqian ZhongSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0000-0001-7858-1077
Xi ChenHunan Provincial Center for Drug Evaluation and Adverse Reaction Monitoring, Changsha 410013, China.
Xinhua XiaSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0000-0003-2630-5585

Funding

Key Discipline Project on Chinese Pharmacology of Hunan University of Chinese Medicine 202302The Hunan Key Research and Development Program No. 2017SK2122the Natural Science Foundation of China No.81573621the Science and Technology Innovation Program of Hunan Province 2021RC4064
6 · The paper itself

Abstract

Conventional cancer treatments often have complications and serious side effects, with limited improvements in 5-year survival and quality of life. Photothermal therapy (PTT) employs materials that convert light to heat when exposed to near-infrared light to raise the temperature of the tumor site to directly ablate tumor cells, induce immunogenic cell death, and improve the tumor microenvironment. This therapy has several benefits, including minimal invasiveness, high efficacy, reduced side effects, and robust targeting capabilities. Beyond just photothermal conversion materials, nanoplatforms significantly contribute to PTT by supplying effective photothermal conversion materials and bolstering tumor targeting to amplify anti-tumor effects. However, the anti-tumor effects of PTT alone are ultimately limited and often need to be combined with other therapies. This narrative review describes the recent progress of PTT combined with chemotherapy, radiotherapy, photodynamic therapy, immunotherapy, gene therapy, gas therapy, chemodynamic therapy, photoacoustic imaging, starvation therapy, and multimodal therapy. Studies have shown that combining PTT with other treatments can improve efficacy, reduce side effects, and overcome drug resistance. Despite the encouraging results, challenges such as optimizing treatment protocols, addressing tumor heterogeneity, and overcoming biological barriers remain. This paper highlights the potential for personalized, multimodal approaches to improve cancer treatment outcomes.

Indexed as

cancer therapyphotothermal therapypre-clinical and clinical studiessynergistic therapy

Identifiers

PMID40142970
PMCPMC11944535

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.